Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 5 (2008), Issue 3 (March)

1. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
   Cancer, 112(5): 1131-8. [Abstract] [Full-text]
2. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
   Cancer, 112(5): 982-94. [Abstract] [Full-text]
3. Sinonasal melanoma: a clinicopathologic review of 61 cases.
   Otolaryngol Head Neck Surg, 138(3): 347-52. [Abstract] [Full-text]
4. Acoustic characterization of a new trisacryl contrast agent. Part II: Flow phantom study and in vivo quantification.
   Ultrasonics, 48(1): 26-34. [Abstract] [Full-text]
5. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study.
   Int J Cancer, 122(9): 2077-84. [Abstract] [Full-text]
6. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor.
   Int J Cancer, 122(9): 1972-80. [Abstract] [Full-text]
7. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines.
   Cancer Res, 68(5): 1362-8. [Abstract] [Full-text]
8. Influence of therapy on the antioxidant status in patients with melanoma.
   J Clin Pharm Ther, 33(2): 179-85. [Abstract] [Full-text]
9. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.
   Histopathology, 52(4): 500-9. [Abstract] [Full-text]
10. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture.
    Ophthalmology, 115(3): 511-519.e2. [Abstract] [Full-text]
11. Learning the ABCs of melanoma-initiating cells.
    Cancer Cell, 13(3): 185-7. [Abstract] [Full-text]
12. MDR1 expression identifies human melanoma stem cells.
    Biochem Biophys Res Commun, 368(4): 930-6. [Abstract] [Full-text]
13. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial.
    Ann Surg Oncol, 15(4): 1218-23. [Abstract] [Full-text]
14. Compliance with melanoma treatment guidelines in a community teaching hospital: time trends and other variables.
    Ann Surg Oncol, 15(4): 1211-7. [Abstract] [Full-text]
15. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
    Ann Surg Oncol, 15(4): 1202-10. [Abstract] [Full-text]
16. Oral mucosal melanoma with unusual clinicopathologic features.
    J Cutan Pathol, 35(4): 392-7. [Abstract] [Full-text]
17. Ber-EP4 enhances the differential diagnostic accuracy of cytokeratin 7 in pagetoid cutaneous neoplasms.
    J Cutan Pathol, 35(4): 366-72. [Abstract] [Full-text]
18. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting.
    J Cutan Pathol, 35(4): 349-52. [Abstract] [Full-text]
19. Terfenadine-induced apoptosis in human melanoma cells is mediated through Ca2+ homeostasis modulation and tyrosine kinase activity, independently of H1 histamine receptors.
    Carcinogenesis, 29(3): 500-9. [Abstract] [Full-text]
20. Hyperthermia induces endoplasmic reticulum-mediated apoptosis in melanoma and non-melanoma skin cancer cells.
    J Invest Dermatol, 128(4): 949-56. [Abstract] [Full-text]
21. Expression of ligands to NKp46 in benign and malignant melanocytes.
    J Invest Dermatol, 128(4): 972-9. [Abstract] [Full-text]
22. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.
    J Invest Dermatol, 128(4): 988-98. [Abstract] [Full-text]
23. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?
    J Invest Dermatol, 128(4): 957-71. [Abstract] [Full-text]
24. mTOR is activated in the majority of malignant melanomas.
    J Invest Dermatol, 128(4): 980-7. [Abstract] [Full-text]
25. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.
    Cancer Res, 68(6): 2006-13. [Abstract] [Full-text]
26. Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma.
    Cancer Res, 68(6): 1997-2005. [Abstract] [Full-text]
27. Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice.
    J Pineal Res, 44(3): 307-15. [Abstract] [Full-text]
28. A cell surface 230 kDa protein from murine melanoma involved with tumor malignancy.
    Cancer Lett, 262(2): 276-85. [Abstract] [Full-text]
29. Hydrodynamic shear rate regulates melanoma-leukocyte aggregation, melanoma adhesion to the endothelium, and subsequent extravasation.
    Ann Biomed Eng, 36(4): 661-71. [Abstract] [Full-text]
30. Thumb reconstruction following resection for malignant tumors.
    Plast Reconstr Surg, 121(4): 1279-87. [Abstract] [Full-text]
31. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells.
    Oncogene, 27(13): 1834-43. [Abstract] [Full-text]
32. Pagetoid lesions of the vulva: a collision between malignant melanoma and extramammary Paget disease.
    Int J Gynecol Pathol, 27(2): 292-6. [Abstract] [Full-text]
33. Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy.
    Am J Dermatopathol, 30(2): 185-7. [Abstract] [Full-text]
34. Identical twins with primary cutaneous melanoma presenting at the same time and location.
    Am J Dermatopathol, 30(2): 182-4. [Abstract] [Full-text]
35. Complete regression of primary malignant melanoma.
    Am J Dermatopathol, 30(2): 178-81. [Abstract] [Full-text]
36. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Am J Dermatopathol, 30(2): 117-22. [Abstract] [Full-text]
37. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Ann Oncol, 19(4): 801-6. [Abstract] [Full-text]
38. Desmoplastic melanoma: the role of radiotherapy in improving local control.
    ANZ J Surg, 78(4): 273-6. [Abstract] [Full-text]
39. Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma.
    Br J Ophthalmol, 92(4): 479-82. [Abstract] [Full-text]
40. Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer.
    Dermatol Surg, 34(4): 483-97. [Abstract] [Full-text]
41. The 20-minute rapid MART-1 immunostain for malignant melanoma frozen sections.
    Dermatol Surg, 34(4): 498-500. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.